**Mycobacterium tuberculosis:** escape room world champion

Thuc Anh Nguyen¹, Sophie Croon¹ and Ger Rijkers¹,²*

An escape room is a physical adventure game in which the players have to solve problems and develop a strategy to leave their confined physical space. In March 2017, Budapest hosted the first escape room championships, in which 22 countries participated; Slovenia won. If this championship would have taken place in the microbiological world, the winner probably would have been *Mycobacterium tuberculosis* (*M. tuberculosis*).

*M. tuberculosis* is the causative micro-organism of the most widespread infectious disease tuberculosis (TB). *M. tuberculosis* can be transmitted via air droplets into the lungs, where it is phagocytosed by alveolar macrophages. Normally, a macrophage would be able kill and digest the pathogen by fusing the phagosome with a lysosome. However, in the case of *M. tuberculosis*, the bacterium can escape this lysosomal fusion which allows the bacterium to replicate and grow intracellularly in the phagocyte [1]. Because lysosomes contain a large arsenal of bactericidal enzymes, the prevention or postponement of fusion with the phagosome thus increases the chance of survival of the bacterium. Ironically, this type of host defense mechanism, phagocytosis, is beneficial to *M. tuberculosis* and other intracellularly growing bacteria such as Mycobacteria, Legionella and Salmonella species and *Listeria monocytogenes*; because by staying within the phagocytic cell, the microorganism is shielded from important components of the immune system including complement and antibodies. They extract the essential nutrients and minerals (including iron) directly from the host cell for their own growth, but in order to survive the intracellular microorganisms has to use ‘stealth’ techniques to escape bactericidal mechanisms of phagocytic cells.

As indicated above, *M. tuberculosis* can be taken up in lysosomes but after two to four days it can break out of the phagolysosome escaping its digestion and evades into the cytoplasm (Fig. 1) [2, 3]. Moreover, the characteristic of *M. tuberculosis* as an escape artist can be further shown by its ability to disseminate from the primary site of infection to peripheral lymph nodes and blood stream [4]. It thus now becomes apparent that the multiple levels of escape mechanisms from the host immune system makes *M. tuberculosis* an extremely pathogenic bacteria.

The current treatment of TB consist of a series of antibiotics which have to be taken for 6 months [5]. A full course of therapy (completion of treatment) is however determined more accurately by the total number of doses taken, not solely by the duration of therapy. For example, the “6-month” daily regimen (given 7 days/week) should consist of at least 182 doses of Isoniazid and Rifampin, and 56 doses of Pyrazinamide [6]. Anti-biotic therapy hasn’t changed much because only one TB drug has entered the clinical practice in the past 40 years. Also in terms of prevention of TB progress is slow. The BCG vaccine has been in use for almost a hundred years, but unfortunately only has a limited effect in preventing tuberculosis [7]. Thus TB remains one of the deadliest infections known to man, causing 10.0 million infections and 1.6 million deaths in 2017 [8].

Combining these figures with the increased rate of infections by multidrug resistant strains, which already account for 50% of infections in some countries [9], means that a more effective vaccine is urgently needed. BCG has shown to protect vaccinees against deadly disseminated forms of TB including life threatening TB meningitis. However, at a later stage of infection when *M. tuberculosis*, BCG becomes ineffective [10].

While BCG mainly induces a cellular immune response, recent research now also focuses on development of vaccines inducing a humoral response, with antibodies against α-glucan, arabinomannan and laptipated arabinomannan [11]. There is a clear need for standardization of experimental designs with aligning of end-points which should facilitate the development of new vaccines [12]. Vaccine candidates, such as the ones mentioned above, could be combined in recombinant viral vectors [13].

* Correspondence: g.rijkers@ucr.nl

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
development of better Mycobacterial vaccines it should also be kept in mind that a supraoptimal immune response may lead to considerable immunopathology [14, 15].

Although *M. tuberculosis* may be successful at escaping the phagolysosome, it is important that it does not escape our attention. Millions of patients are affected each year, and fully effective vaccines have not yet been developed. In order for this disease to stay on the radar, there is an annual World Tuberculosis Day on March 24. During this day, special attention is given to the victims of this infection, and to promote research leading to a better future for those that are currently infected, and those that will be infected in the future. Together, these efforts hopefully succeed in eradication of this disease, so that in the future it will fail to escape our attention once and for all.

Acknowledgements
Figure 1 courtesy of Professor Peter Peters, Institute of Nanoscopy, Maastricht University, The Netherlands.

Funding
No external funding was used for this work.

Authors’ contributions
GTR conceived the idea for this editorial. TAN, SC, and GTR together wrote the manuscript. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 22 February 2019 Accepted: 8 March 2019
Published online: 24 March 2019

References
1. Rohde K, Yates RM, Purdy GE, Russell DG. Mycobacterium tuberculosis and the environment within the phagosome. Immunol Rev. 2007;219(1):37–54.
2. van der Wel N, Hava D, Houben D, Fluitsma D, van Zon M, Pierson J, Brenner M, Peters PJ, M. Tuberculosis and M. Leproae translocate from the phagolysosome to the cytosol in myeloid cells. Cell. 2007;129(7):1287–98.
3. Delogu G, Provvedi R, Sali M, Manganelli R. Mycobacterium tuberculosis virulence: insights and impact on vaccine development. Future Microbiol. 2015;10(7):1177–94.
4. Krishnan N, Robertson BD, Thwaites G. The mechanisms and consequences of the extra-pulmonary dissemination of Mycobacterium tuberculosis. Tuberculosis. 2010;90(6):361–6.
5. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etzkind SC, Friedman LN, Fujikawa P, Grzemba M, Hopewell PC, Iseman MD, Jasmer RM, Koppaka V, Menzies RI, O’Brien RJ, Reves RR, Reichman LB, Simone PM, Starke JR, Vernon AA, American Thoracic Society, Centers for Disease Control and Prevention and the infectious diseases society. American Thoracic Society/ Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003;167(4):603–62.
6. Chakraborty S, Rhee KY. Tuberculosis drug development: history and evolution of the mechanism-based paradigm. Cold Spring Harb Perspect Med. 2015;5(8):a021147.
7. Roy A, Eisenhut M, Harris RJ, Rodrigues LC, Sridhar S, Habermann S, Abubakar I. Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis. Br Med J. 2014;349:g4643.
8. WHO. Global tuberculosis report 2018. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO. https://apps.who.int/iris/bitstream/handle/10665/274453/9789241565646-eng.pdf Accessed February 14, 2019.
9. Gheda K, Gumbo T, Maatens G, Dooley KE, McNerney R, Murray M, Theron G. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. The Lancet Resp Med. 2017;5(4):291–360.
10. Gonzalo-Asensio J, Aguilo N, Matinova D, Martin C. Breaking transmission with vaccines: the case of tuberculosis. Microbiol Spectrum. 2017;5(4):1–11.
11. Achkar JM, Prados-Rosales R. Updates on antibody functions in *Mycobacterium tuberculosis* infection and their relevance for developing a vaccine against tuberculosis. Current Opinion Immunol. 2018;53:30–7.

12. Laddy DJ, Bonavia A, Hanekom WA, Kauhal D, Williams A, Roederer M, Darrah PA. Toward tuberculosis vaccine development: recommendations for nonhuman primate study design. Infect Immun. 2018;86(2):e00776–17.

13. Kaufmann SH, Weiner J, von Reyn CF. (2017). Novel approaches to tuberculosis vaccine development. Intern J Infect Dis. 2017;56:263–7.

14. Sakai S, Kauffman KD, Sallin MA, Sharpe AH, Young HA, Ganusov VV, Barber DL. CD4 T cell-derived IFN-gamma plays a minimal role in control of pulmonary Mycobacterium tuberculosis infection and must be actively repressed by PD-1 to prevent lethal disease. PLoS Pathog. 2016;12:1–22.

15. Cliff JM, Cho JE, Lee JS, Ronacher K, King EC, van Helden P. Excessive cytolytic responses predict tuberculosis relapse after apparently successful treatment. J Infect Dis. 2016;213:485–95.